Google
TLSA — TIZIANA LIFE SCIENCES LTD (Healthcare >> Biotechnology)
TLSA FAQ
What is TLSA's ROE?
TIZIANA LIFE SCIENCES LTD reports a Return on Equity (ROE) of -60,138.46%.
What is TLSA's dividend yield?
TIZIANA LIFE SCIENCES LTD offers a dividend yield of 0.00%.
What is TLSA's Deepscope Quality Score?
Deepscope rates TLSA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TLSA?
Deepscope's AI Timing Score for TLSA is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TLSA belong to?
TIZIANA LIFE SCIENCES LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.22
Price
-0.02
(-1.61%)
Day Change
|
|
|---|
TLSA, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.22 |
| PBV / Sector |
3,034.64 / 4.75
|
| Earning Per Share | -0.24 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
0.38 M
GREAT
|
| Average 1W Daily Value |
0.30 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-09 09:40:12 |
| Symbol | TLSA |
| Name | TIZIANA LIFE SCIENCES LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 127.26 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 157.80 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 14/15 Conduit Street, London, United Kingdom, W1S 2XJ
Phone: 44 20 7495 2379
Website: https://www.tizianalifesciences.com
Sector: Healthcare >> Biotechnology
Description: Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
